Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05923190 · ClinicalTrials.gov registry record · Phase 2
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
A Phase 2 study of Urothelial Carcinoma and Metastatic Urothelial Carcinoma, sponsored by Fox Chase Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05923190 is a Phase 2 study of Urothelial Carcinoma and Metastatic Urothelial Carcinoma that is active but no longer recruiting, run by Fox Chase Cancer Center. The registered enrollment target is 60 participants, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05923190, a Phase 2 study of Urothelial Carcinoma and Metastatic Urothelial Carcinoma, is active but no longer recruiting, sponsored by Fox Chase Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-randomized two arm open-label phase 2 pilot study in adult subjects with locally advanced or metastatic urothelial cancer. The study will investigate an alternative administration schedule of EV given as monotherapy and in combination with pembrolizumab.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Enfortumab vedotin
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-06-14 |
| Est. Completion | 2029-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05923190
The ClinicalTrials.gov registry entry for NCT05923190 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (75% lower). The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05923190 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05923190 about?
NCT05923190 is a clinical study titled "Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma". This is a non-randomized two arm open-label phase 2 pilot study in adult subjects with locally advanced or metastatic urothelial cancer. The study will investigate an alternative administration schedule of EV given as monotherapy and in combination with pembrolizumab.
What is the current status of trial NCT05923190?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-06-14. Estimated completion is 2029-07-01.
What conditions does trial NCT05923190 study?
This clinical trial studies the following conditions: Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma.
What interventions are being tested in trial NCT05923190?
The interventions under investigation include: Pembrolizumab (DRUG), Enfortumab vedotin (DRUG).
Who is sponsoring clinical trial NCT05923190?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05923190 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RECRUITING · Phase 2
-
Circulating Tumor DNA Response In Urothelial Cancer
RECRUITING · Phase 2
-
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RECRUITING · Phase 2
-
Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence
RECRUITING · Phase 2
-
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
RECRUITING · Phase 2
-
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.